Summary by Moomoo AI
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced on February 1, 2024, an exclusive long-term licensing agreement with BIRAD, the research and development arm of Bar-Ilan University in Israel. This agreement grants Clearmind the rights to use a joint patent with BIRAD for an innovative treatment for cocaine addiction. The treatment is based on the compound MEAI [5-Methoxy-2-aminoindane], which has shown promising results in pre-clinical trials by significantly reducing cocaine craving and addiction. The trials, led by Professor Gal Yadid at the Gonda Multidisciplinary Brain Research Center, utilized the self-administration paradigm to demonstrate MEAI's potential in treating cocaine addiction without being addictive itself. Clearmind's CEO, Dr. Adi Zuloff-Shani, expressed that securing the exclusive rights aligns with the company's strategic decision to ensure maximum returns for shareholders and to provide innovative treatments for addiction. The company's shares are traded on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY' respectively.